# BiVictriX Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/bivictrix-therapeutics

- Industry: Biotechnology
- Headquarters: Cheshire, UK
- Website: www.bivictrix.com
- Total disclosed funding: $0.4M
- Latest round: Seed (Jul 30, 2019)
- Investors on record: 2

## About

BiVictriX Therapeutics Ltd. is focused on developing innovative cancer therapeutics using its proprietary Bi-Cygni® platform to enhance targeting and treatment precision against aggressive cancers.Founded in 2016, BiVictriX Therapeutics Ltd. is based in Cheshire, UK, and specializes in cancer therapeutic development. The company has completed 2 deals, with its most recent funding round occurring on September 16, 2020. Tiffany Thorn serves as both the CEO and Founder of the company.BiVictriX is primarily focused on developing next-generation cancer therapeutics through its proprietary Bi-Cygni® platform. This innovative approach aims to 'un-mask' cancer cells, making them visible and vulnerable to targeted therapies. The core offerings include antibody-drug conjugates (ADCs) that effectively combine the selective targeting capability of antibodies with the potent efficacy of chemotherapy agents. These ADCs are engineered to release their cytotoxic components only upon binding to specific targets on the cancer cell surface, thereby reducing harm to healthy cells. The company's products are designed to address some of the most aggressive cancers, enhancing the precision of cancer treatments. BiVictriX is actively pursuing markets in North America and Europe, aiming to deliver these advanced therapeutics to a diverse range of healthcare providers and patients suffering from difficult-to-treat malignancies.BiVictriX generates revenue through partnerships with healthcare providers, pharmaceutical companies, and research institutions focused on oncology. The revenue model typically involves collaborations and licensing agreements, wherein clients access the Bi-Cygni® platform for the development of tailored cancer therapies. These transactions are structured around significant milestones, such as preclinical and clinical trial advancements, which may involve upfront payments and royalties on future sales of the products developed. The company's flagship offering, the Bi-Cygni® ADCs, is positioned to enter the market through strategic partnerships, enabling broader distribution among hospitals and clinics specializing in cancer treatment. Through these collaborations, BiVictriX aims to not only enhance treatment options but also ensure that clinicians can administer more effective doses while minimizing side effects for patients. For the year 2024, BiVictriX reported an EBITDA amount of GBP -2,254,915.20.BiVictriX Therapeutics Ltd. plans to utilize the GBP 1 million raised in September 2020 to support product development and market expansion. The company is focused on the ongoing development and launch of new cancer therapeutics designed through its Bi-Cygni® platform. BiVictriX aims to expand its presence in North America and Europe, targeting healthcare providers and institutions by the end of 2024. Recent funding will facilitate these initiatives, positioning the company to enhance its product offerings and increase accessibility to innovative cancer treatments.

## Funding rounds

- Seed, Jul 30, 2019, $0.4M — Development Bank of Wales, Alderley Park Ventures

## Investors

- Development Bank of Wales (https://capitalatlas.ai/funds/development-bank-of-wales) — Seed
- Alderley Park Ventures — Seed